β-肾上腺素能受体阻滞剂治疗是否能改善癌症患者的生存？一项基于人群的回顾性队列研究的结果。
Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study.
机构信息
Division of Population Health Sciences and Education, St George's University of London, Tooting, London SW17 0RE, UK.
出版信息
Br J Clin Pharmacol. 2011 Jul;72(1):157-61. doi: 10.1111/j.1365-2125.2011.03980.x.
Abstract
AIMS
To examine the effect of β-adrenoceptor blocker treatment on cancer survival.
METHODS
In a UK primary care database, we compared patients with a new cancer diagnosis receiving β-adrenoceptor blockers regularly (n= 1406) with patients receiving other antihypertensive medication (n= 2056).
RESULTS
Compared with cancer patients receiving other antihypertensive medication, patients receiving β-adrenoceptor blocker therapy experienced slightly poorer survival (HR = 1.18, 95% CI 1.04, 1.33 for all β-adrenoceptor blockers; HR = 1.21, 95% CI 0.94, 1.55 for non-selective β-adrenoceptor blockers). This poorer overall survival was explained by patients with pancreatic and prostate cancer with no evidence of an effect on survival for patients with lung, breast or colorectal cancer. Analysis in a cancer-free matched parallel cohort did not suggest selection bias masked a beneficial effect.
CONCLUSION
Our study does not support the hypothesis that β-adrenoceptor blockers improve survival for common cancers.
摘要
目的
研究β受体阻滞剂治疗对癌症患者生存的影响。
方法
在英国初级保健数据库中，我们比较了新诊断患有癌症且经常接受β受体阻滞剂治疗的患者（n=1406）与接受其他降压药物治疗的患者（n=2056）。
结果
与接受其他降压药物治疗的癌症患者相比，接受β受体阻滞剂治疗的患者生存状况略差（所有β受体阻滞剂的 HR=1.18，95%CI1.04，1.33；非选择性β受体阻滞剂的 HR=1.21，95%CI0.94，1.55）。这种总体生存率较差的情况可以解释为患有胰腺癌和前列腺癌的患者，而对于患有肺癌、乳腺癌或结直肠癌的患者，其生存没有证据表明存在影响。在无癌症的匹配平行队列中进行的分析并未表明选择偏差掩盖了有益的效果。
结论
我们的研究不支持β受体阻滞剂可改善常见癌症患者生存的假设。
相似文献
1
Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study.β-肾上腺素能受体阻滞剂治疗是否能改善癌症患者的生存？一项基于人群的回顾性队列研究的结果。
Br J Clin Pharmacol. 2011 Jul;72(1):157-61. doi: 10.1111/j.1365-2125.2011.03980.x.
2
Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study.对电子病历的分析能否进行独立的外部验证？研究2——β-肾上腺素能受体阻滞剂治疗对癌症生存率的影响：一项回顾性队列研究。
BMJ Open. 2015 Apr 13;5(4):e007299. doi: 10.1136/bmjopen-2014-007299.
3
Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness.β受体阻滞剂在高血压治疗中的药物干预：长期有效性的真实世界证据。
Pharmacol Res. 2018 Apr;130:191-197. doi: 10.1016/j.phrs.2018.01.010. Epub 2018 Jan 31.
4
Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients.β肾上腺素能受体阻滞剂与肝癌患者肝癌死亡率的全国队列研究。
Scand J Gastroenterol. 2020 May;55(5):597-605. doi: 10.1080/00365521.2020.1762919. Epub 2020 May 15.
5
Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.药物流行病学研究中癌症患者生存的不朽时间偏倚：不同预后的四种癌症中β受体阻滞剂使用的实证说明。
Eur J Epidemiol. 2017 Nov;32(11):1019-1031. doi: 10.1007/s10654-017-0304-5. Epub 2017 Sep 1.
6
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.在接受根治性放疗的非小细胞肺癌患者中，偶然使用β受体阻滞剂可改善生存结局。
Ann Oncol. 2013 May;24(5):1312-9. doi: 10.1093/annonc/mds616. Epub 2013 Jan 8.
7
Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.选择性和非选择性β受体阻滞剂对卵巢癌患者生存率的临床影响。
Cancer. 2015 Oct 1;121(19):3444-51. doi: 10.1002/cncr.29392. Epub 2015 Aug 24.
8
Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.使用血管紧张素转换酶抑制剂和β受体阻滞剂会降低原发性肝癌风险吗？一项基于英国临床实践研究数据链的病例对照研究。
Pharmacotherapy. 2016 Feb;36(2):187-95. doi: 10.1002/phar.1704. Epub 2016 Feb 5.
9
Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.心脏选择性与非选择性β受体阻滞剂在终末期肾病中的有效性比较及其与死亡率和发病率的关联：一项回顾性队列研究
BMC Cardiovasc Disord. 2016 Mar 25;16:60. doi: 10.1186/s12872-016-0233-3.
10
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer.β受体阻滞剂用于转移性结直肠癌的偶然降压治疗的预后价值
Medicine (Baltimore). 2015 Jun;94(24):e719. doi: 10.1097/MD.0000000000000719.
引用本文的文献
1
Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm.针对结直肠癌中β-肾上腺素能受体的药物干预：一种不断发展的模式。
Inflammopharmacology. 2025 Sep 15. doi: 10.1007/s10787-025-01925-5.
2
Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation.β受体阻滞剂对癌症神经免疫学的影响：生存结局与免疫调节的系统评价和荟萃分析
Front Immunol. 2025 Aug 6;16:1635331. doi: 10.3389/fimmu.2025.1635331. eCollection 2025.
3
The Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis.β受体阻滞剂对癌症患者生存的影响：一项系统评价和荟萃分析
Cancers (Basel). 2025 Apr 18;17(8):1357. doi: 10.3390/cancers17081357.
4
Beta-adrenergic receptor blockers improve survival in patients with advanced non-small cell lung cancer combined with hypertension undergoing radiotherapy.β-肾上腺素能受体阻滞剂可提高晚期非小细胞肺癌合并高血压接受放疗患者的生存率。
Sci Rep. 2025 Mar 28;15(1):10702. doi: 10.1038/s41598-025-93205-z.
5
β-Blockers Influence Oncological Outcomes in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy Based on the Pathological Subtype: A Retrospective Cohort Study.基于病理亚型的新辅助化疗治疗胃癌患者中β受体阻滞剂对肿瘤学结局的影响：一项回顾性队列研究
Ann Surg Oncol. 2025 Mar 25. doi: 10.1245/s10434-025-17233-9.
6
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.贝伐珠单抗联合治疗转移性肾细胞癌的效果分析
Eur J Clin Pharmacol. 2024 Jun;80(6):941-947. doi: 10.1007/s00228-024-03668-8. Epub 2024 Mar 13.
7
Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies.交感神经系统功能增强会损害肺癌患者的预后：临床研究的范围综述
Lung Cancer Manag. 2024 Jan 16;12(4):LMT63. doi: 10.2217/lmt-2023-0006. eCollection 2023 Dec.
8
Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC).晚期胰腺导管腺癌患者使用β受体阻滞剂与生存结局：一项回顾性队列研究（BETAPANC）
Front Pharmacol. 2023 May 19;14:1137791. doi: 10.3389/fphar.2023.1137791. eCollection 2023.
9
Chronic stress in solid tumor development: from mechanisms to interventions.慢性应激在实体瘤发展中的作用：从机制到干预。
J Biomed Sci. 2023 Jan 28;30(1):8. doi: 10.1186/s12929-023-00903-9.
10
Profiling the Adrenergic System in Breast Cancer and the Development of Metastasis.乳腺癌中肾上腺素能系统剖析与转移的发生
Cancers (Basel). 2022 Nov 10;14(22):5518. doi: 10.3390/cancers14225518.
本文引用的文献
1
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.β受体阻滞剂药物治疗可减少乳腺癌的继发性肿瘤形成，并提高癌症特异性生存率。
Oncotarget. 2010 Nov;1(7):628-638. doi: 10.18632/oncotarget.197.
2
Sympathetic Neurotransmitters and Tumor Angiogenesis-Link between Stress and Cancer Progression.交感神经递质与肿瘤血管生成——应激与癌症进展的联系。
J Oncol. 2010;2010:539706. doi: 10.1155/2010/539706. Epub 2010 May 20.
3
β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1.β2-肾上腺素能拮抗剂通过抑制 CREB、NFκB 和 AP-1 抑制胰腺癌细胞侵袭。
Cancer Biol Ther. 2010 Jul 1;10(1):19-29. doi: 10.4161/cbt.10.1.11944.
4
Prevention of pancreatic cancer by the beta-blocker propranolol.β受体阻滞剂普萘洛尔预防胰腺癌。
Anticancer Drugs. 2009 Jul;20(6):477-82. doi: 10.1097/CAD.0b013e32832bd1e3.
5
Catecholamines regulate tumor angiogenesis.儿茶酚胺调节肿瘤血管生成。
Cancer Res. 2009 May 1;69(9):3727-30. doi: 10.1158/0008-5472.CAN-08-4289. Epub 2009 Apr 21.
6
Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell.普萘洛尔通过诱导凋亡抑制胰腺癌细胞增殖：β-肾上腺素能受体拮抗剂对胰腺癌细胞抗癌作用的研究
Pancreas. 2009 Jan;38(1):94-100. doi: 10.1097/MPA.0b013e318184f50c.
7
Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression.去甲肾上腺素上调人黑色素瘤肿瘤细胞系中VEGF、IL-8和IL-6的表达：对与应激相关的肿瘤进展增强的影响。
Brain Behav Immun. 2009 Feb;23(2):267-75. doi: 10.1016/j.bbi.2008.10.005. Epub 2008 Oct 21.
8
Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway.肾上腺素通过β-肾上腺素能受体依赖的细胞外信号调节激酶/环氧化酶-2途径的反式激活刺激食管鳞状细胞癌细胞增殖。
J Cell Biochem. 2008 Sep 1;105(1):53-60. doi: 10.1002/jcb.21802.
9
Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials.抗高血压药物及其对癌症发病率的影响：随机对照试验的混合治疗比较荟萃分析
J Hypertens. 2008 Apr;26(4):622-9. doi: 10.1097/HJH.0b013e3282f3ef5e.
10
The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers.β受体阻滞剂可抑制去甲肾上腺素驱动的PC-3人前列腺癌细胞在BALB/c裸鼠体内的转移发展。
Int J Cancer. 2006 Jun 1;118(11):2744-9. doi: 10.1002/ijc.21723.
Zotero 插件